Evidence map›Paper›PMID 32427591›Full record

ArticleThe Journal of clinical investigation2020

Noggin regulates foregut progenitor cell programming, and misexpression leads to esophageal atresia.

Carolina Pinzon-Guzman, Sreedhara Sangadala, Katherine M Riera, Evgenya Y Popova, Elizabeth Manning, Won Jae Huh, Matthew S Alexander, Julia S Shelton, Scott D Boden, James R Goldenring

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Carolina Pinzon-GuzmanDepartment of Surgery, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Sreedhara SangadalaDepartment of Orthopedics, Emory School of Medicine, Atlanta, Georgia, USA.
Katherine M RieraDepartment of Surgery, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Evgenya Y PopovaDepartment of Neural and Behavioral Sciences, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Elizabeth ManningDepartment of Surgery, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Won Jae HuhDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Matthew S AlexanderUniversity of Iowa Hospitals and Clinics, Department of Surgery, Iowa City, Iowa, USA.
Julia S SheltonUniversity of Iowa Stead Family Children's Hospital, Iowa City, Iowa, USA.
Scott D BodenDepartment of Orthopedics, Emory School of Medicine, Atlanta, Georgia, USA.
James R GoldenringDepartment of Surgery, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Vanderbilt University Medical Center · USEmory University · USNashville VA Medical Center · USPennsylvania State University · USUniversity of Iowa Hospitals and Clinics · USUniversity of Iowa Stead Family Children’s Hospital · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Surgical Oncology Training GrantT32CA106183 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI James Richard Goldenring · 2004 to 2026
$6.0M
Mechanisms of Gastric Mucous Cell MetaplasiaR01DK071590 · NIDDK · VANDERBILT UNIVERSITY · PI GOLDENRING, JAMES RICHARD · 2008 to 2012
$2.2M
Application of a Repurposed FDA Approved Drug as a Local Osteogenic AgentR21TR001751 · NCATS · EMORY UNIVERSITY · PI SANGADALA, SREEDHARA, WILLETT, NICK J · 2017 to 2018
$513k
BLRD VA I01 BX000930BLRD VA IS1 BX003097NCATS NIH HHS R21 TR001751NCI NIH HHS P30 CA068485NCI NIH HHS T32 CA106183NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK071590
6 · The paper itself

Abstract

Esophageal atresia (EA/TEF) is a common congenital abnormality present in 1 of 4000 births. Here we show that atretic esophagi lack Noggin (NOG) expression, resulting in immature esophagus that contains respiratory glands. Moreover, when using mouse esophageal organoid units (EOUs) or tracheal organoid units (TOUs) as a model of foregut development and differentiation in vitro, NOG determines whether foregut progenitors differentiate toward esophageal or tracheal epithelium. These results indicate that NOG is a critical regulator of cell fate decisions between esophageal and pulmonary morphogenesis, and its lack of expression results in EA/TEF.

Indexed as

Cell DifferentiationGene Expression Regulation, DevelopmentalModels, BiologicalAnimalsCarrier ProteinsCell LineEsophageal AtresiaHumansMiceNoggin ProteinOrganoidsStem CellsCarrier ProteinsNoggin ProteinDevelopmentEmbryonic developmentHuman stem cellsSurgery

Identifiers

PMID32427591
PMCPMC7410075
OpenAlexW3027896649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.